TVRD
NASDAQTvardi Therapeutics
$3.80
-1.20 (-24.00%)
2026-07-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$18.3M
P/E Ratio
N/A
52W Low
52W High
$1.50
$43.65
Volume
7.4M
Analyst Rating
Hold
Target: $8
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $8
Avg: $8
High: $9
About Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis ...
Employees
12
Website
tvarditherapeutics.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$18.2M | -$23.5M |
| 2024 | $7.1M | -781.6% | -$70.9M | -$59.9M |
| 2023 | $21.0M | -579.4% | -$118.5M | -$18.7M |
| 2022 | $41.9M | -209.1% | -$85.5M | -$17.8M |
| 2021 | $23.0M | -386.8% | -$88.4M | -$60.0M |
| 2026 Q1 | N/A | N/A% | -$6.8M | -$5.9M |
| 2025 Q4 | N/A | N/A% | -$7.3M | -$5.7M |
| 2025 Q3 | N/A | N/A% | -$5.5M | -$4.3M |
| 2025 Q2 | N/A | N/A% | $4.2M | -$8.9M |
| 2025 Q1 | $2.6M | -92.9% | -$4.9M | -$7.7M |
| 2024 Q4 | $1.5M | -742.4% | -$12.7M | -$4.0M |
| 2024 Q3 | $2.6M | -222.1% | -$5.5M | -$14.0M |
| 2024 Q2 | $991K | -724.6% | -$7.0M | -$12.2M |